JP2018536621A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536621A5
JP2018536621A5 JP2018511684A JP2018511684A JP2018536621A5 JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5 JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5
Authority
JP
Japan
Prior art keywords
independently
xaa
cancer
macrocycle
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536621A (ja
JP6971970B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050194 external-priority patent/WO2017040990A1/en
Publication of JP2018536621A publication Critical patent/JP2018536621A/ja
Publication of JP2018536621A5 publication Critical patent/JP2018536621A5/ja
Application granted granted Critical
Publication of JP6971970B2 publication Critical patent/JP6971970B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511684A 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用 Expired - Fee Related JP6971970B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562214142P 2015-09-03 2015-09-03
US62/214,142 2015-09-03
US201662310254P 2016-03-18 2016-03-18
US62/310,254 2016-03-18
US201662344651P 2016-06-02 2016-06-02
US201662344791P 2016-06-02 2016-06-02
US62/344,651 2016-06-02
US62/344,791 2016-06-02
PCT/US2016/050194 WO2017040990A1 (en) 2015-09-03 2016-09-02 Peptidomimetic macrocycles and uses thereof

Publications (3)

Publication Number Publication Date
JP2018536621A JP2018536621A (ja) 2018-12-13
JP2018536621A5 true JP2018536621A5 (enExample) 2019-10-17
JP6971970B2 JP6971970B2 (ja) 2021-11-24

Family

ID=58188595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511684A Expired - Fee Related JP6971970B2 (ja) 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用

Country Status (11)

Country Link
US (2) US20170114098A1 (enExample)
EP (1) EP3344275B8 (enExample)
JP (1) JP6971970B2 (enExample)
KR (1) KR20180043835A (enExample)
CN (1) CN108348571B (enExample)
AU (1) AU2016315878A1 (enExample)
BR (1) BR112018003985A2 (enExample)
CA (1) CA2996685A1 (enExample)
IL (1) IL257706A (enExample)
MX (1) MX2018002723A (enExample)
WO (1) WO2017040990A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960506B2 (en) 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Mcl−1のモジュレーターとしてのペプチド模倣大環状分子
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TW201818934A (zh) * 2016-10-17 2018-06-01 日商第一三共股份有限公司 Mdm2抑制劑與dna甲基轉移酶抑制劑之倂用治療法
JP2019537585A (ja) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Ezh2媒介性がんを治療するための組成物および方法
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
JP2020519595A (ja) * 2017-05-11 2020-07-02 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
WO2018223040A1 (en) * 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
JP2021527666A (ja) 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ Wd40反復ドメインタンパク質5(wdr5)分解/破壊化合物および使用の方法
WO2020023502A1 (en) * 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20210044251A (ko) 2018-08-13 2021-04-22 베이징 페르칸스 온콜로지 컴퍼니 리미티드 암 치료용 바이오마커
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020112868A1 (en) * 2018-11-30 2020-06-04 Aileron Therapeutics, Inc. Combination therapy of peptidomimetic macrocycles
AR116904A1 (es) * 2018-12-11 2021-06-23 Kartos Therapeutics Inc Métodos y composiciones para el tratamiento de un trastorno oftálmico
CN109731104A (zh) * 2018-12-29 2019-05-10 苏州明基医院有限公司 一种多肽-稀土材料递送系统及制备方法和应用
CN114173878A (zh) * 2019-03-15 2022-03-11 艾瑞朗医疗公司 拟肽大环化合物及其用途
WO2020198734A1 (en) * 2019-03-28 2020-10-01 The Penn State Research Foundation Methods, compositions relating to treatment of cancer
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
WO2021202961A1 (en) * 2020-04-02 2021-10-07 United States As Represented By Dept Of Veterans Affairs Methods of treating immunotherapy resistant metastatic melanoma
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
IL298592A (en) 2020-06-24 2023-01-01 Pmv Pharmaceuticals Inc Combination therapy for treatment of cancer
CN111825621A (zh) * 2020-07-22 2020-10-27 天津理工大学 一种奥拉帕尼与丙二酸的共晶及其制备方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用
WO2024083223A1 (zh) * 2022-10-21 2024-04-25 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
GB202219576D0 (en) * 2022-12-22 2023-02-08 Univ Court Univ Of Glasgow Polypeptides
AU2024361979A1 (en) * 2023-10-20 2026-03-05 Alkermes, Inc. Compound for use in treating narcolepsy
WO2025096608A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Egfr covalent inhibition with macrocycles

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターpd−1に対する抗体
CN103951541A (zh) 2008-01-25 2014-07-30 波士顿学院董事会 用于催化包括对映选择性烯烃复分解的复分解反应的方法
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
JP2012509902A (ja) * 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド 改善された特性を有するペプチド模倣大環状分子
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011097642A1 (en) 2010-02-08 2011-08-11 Trustees Of Boston College Efficient methods for z- or cis-selective cross-metathesis
KR20130099938A (ko) * 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
NZ627528A (en) * 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2817023A4 (en) * 2012-02-22 2015-11-25 Univ New York REVERSIBLE NETWORKED SCREW-MOUNTED HYDROGEN BONDING SUPPLY MACROCYCLES
WO2015082384A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
MX389354B (es) * 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
MX2017003797A (es) * 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016154058A1 (en) * 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Similar Documents

Publication Publication Date Title
JP6971970B2 (ja) ペプチド模倣大環状分子およびその使用
JP2018536621A5 (enExample)
CN109414470A (zh) 用于拟肽大环化合物的伴随诊断工具
US11091522B2 (en) Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) ペプチド模倣大環状分子およびその使用
CN106999541A (zh) 拟肽大环化合物及其用途
JP2020519595A (ja) ペプチド模倣大環状分子およびその使用
CN114173878A (zh) 拟肽大环化合物及其用途
WO2020112868A1 (en) Combination therapy of peptidomimetic macrocycles
HK40043424A (en) Peptidomimetic macrocycles and uses thereof